GSK plc is named among the 15 Global Dividend Stocks to Diversify Your Portfolio. HSBC analyst Rajesh Kumar raised GSK’s price target to 1,500 GBp from 1,200 GBp, citing pharmaceutical sector outperformance potential in 2026. FDA approved GSK’s add-on treatment for severe asthma, but not for chronic rhinosinusitis with nasal polyps. GSK focuses on respiratory disease, immunology, and infectious diseases.

Read more at Yahoo Finance: HSBC Sees Pharma Poised to Outperform in 2026, Lifts GSK Target